Real-world assessment of concomitant opioid utilization and associated trends in patients with migraine

Kangethe, Anne; Polson, Michael; Evangelatos, Themmi; Speicher, Lindsay C; Tenaglia, Andrew T; Staats, Peter S.; Liebler, Eric; Mwamburi, M

doi:10.37765/ajmc.2020.42544

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most relevant finding in this analysis was the identification of a 64% higher adjusted probability of receiving an opioid again in the 12 months following its first prescription. This is consistent with other studies that have reported an increase in this risk after a first prescription, not only in migraine [ 23 , 24 , 25 ], but also during consultations for pain of other origins in emergency services and general care settings [ 11 ]. The prudent use of opioids is of great relevance in indications in which they are clearly recommended, especially for the management of migraine, since they have been associated with chronic use [ 26 ].…”

Section: Discussionsupporting

confidence: 92%

Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia

Machado-Duque,

Echeverry-Gutiérrez,

Gaviria-Mendoza

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Research objective: To identify the frequency of opioid use in a group of patients diagnosed with migraine in Colombia. Methods: Study of a retrospective cohort of patients with a diagnosis of migraine and a first prescription of antimigraine drugs from emergency services and a priority outpatient clinic. Sociodemographic, clinical, and pharmacological variables were identified; a 12-month follow-up was carried out to identify the use of a new opioid. Results: A total of 6309 patients with a diagnosis of migraine were identified, with a mean age of 35.5 ± 12.3 years, of which 81.3% were women. Nonsteroidal anti-inflammatory drugs (51.1%) were the most frequently prescribed medications, followed by ergotamine + caffeine (31.3%), acetaminophen (15.05%), and acetaminophen + codeine (14.4%). At the time of the index, 1300 (20.6%) patients received some opioid. During the follow-up, a total of 1437 (22.8%) patients received a new opioid, of which 31.8% belonged to the group that received an initial opioid and 20.4% to the group that did not receive one, which was statistically significant (OR:1.81; 95%CI:1.58–2.07; p < 0.001). Conclusions: The frequent use of opioids in the management of migraines is potentially inappropriate and can lead to problems of tolerance, abuse and dependence. This combined with the low prescription of triptans, offers an opportunity for improvements in medical practice.

show abstract

Section: Discussionsupporting

confidence: 92%

Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia

Machado-Duque,

Echeverry-Gutiérrez,

Gaviria-Mendoza

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…At the same time, increased use of less expensive opioids in non-persistent patients was aligned with a decrease in costs. As has been shown in more recent research, patients using opioids have greater overall healthcare costs compared to patients not using opioids—up to double for patients using the highest doses of opioids [ 21 ]. Thus, the trade-off between increased use of a more expensive migraine-specific acute medication and the reduced use of a less expensive but more costly overall non-migraine-specific and addictive pain medication may be more than justified.…”

Section: Discussionmentioning

confidence: 99%

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

et al. 2021

View full text Add to dashboard Cite

Introduction: Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns. Methods: We completed a retrospective review of US data (through May 2019) from the IBM MarketScan Ò Early View Databases, identifying adult patients newly treated with erenumab with a migraine claim in the year prior to first erenumab claim (index) and at least 1 year of continuous pre-index medical and pharmacy insurance coverage, to assess pre-and post-erenumab migraine characteristics, comorbidities, healthcare resource utilization, and associated costs. All data were summarized using descriptive statistics. Results: A total of 9753 patients met inclusion criteria. The average (SD) age was 46 (12) years,

show abstract

Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center

et al. 2022

View full text Add to dashboard Cite

Real-world assessment of concomitant opioid utilization and associated trends in patients with migraine

Cited by 4 publications

References 0 publications

Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia

Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center

Contact Info

Product

Resources

About